Dr Michael V Arnett, MD | |
Bassett Army Community Hospital, 4076 Neely Rd., Fort Wainwright, AK 99703 | |
(907) 361-5172 | |
Not Available |
Full Name | Dr Michael V Arnett |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | Bassett Army Community Hospital, Fort Wainwright, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659361459 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | MDR-4635 (Hawaii) | Secondary |
2083X0100X | Preventive Medicine - Occupational Medicine | 49455 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Michael V Arnett, MD 4076 Neely Rd, Fort Wainwright, AK 99703 Ph: () - | Dr Michael V Arnett, MD Bassett Army Community Hospital, 4076 Neely Rd., Fort Wainwright, AK 99703 Ph: (907) 361-5172 |
News Archive
Front-line physicians are advised to err on the side of caution and opt for additional imaging and second opinions when diagnosing six common foot and ankle injuries.
A large study of more than 9,000 men has established harmonized reference ranges for total testosterone in men that when applied to assays that have been appropriately calibrated will effectively enable clinicians to make a correct diagnosis of hypogonadism, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice.
Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.
› Verified 6 days ago